Stocks TelegraphStocks Telegraph
Stock Ideas

CNTB Company Profile and Key Details

NASDAQ : CNTB

Connect Biopharma

$2.15
-0.08-3.59%
At Close 4:00 PM
61.88
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Connect Biopharma Holdings Limited (CNTB) stock declined over -3.59%, trading at $2.15 on NASDAQ, down from the previous close of $2.23. The stock opened at $2.17, fluctuating between $2.15 and $2.25 in the recent session.

Stock Snapshot

2.23
Prev. Close
120.18M
Market Cap
2.15
Day Low
-2.42
P/E Ratio
-0.89
EPS (TTM)
-570.18
Cash Flow per Share
2.17
Open
55.9M
Number of Shares
2.25
Day High
25.74%
Free Float in %
1834.41
Book Value
38.44K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jan 09, 20262.232.252.142.1537.24K
Jan 08, 20262.332.362.182.2383.34K
Jan 07, 20262.282.372.212.3521.15K
Jan 06, 20262.392.442.262.2664.28K
Jan 05, 20262.522.522.352.4069.02K
Jan 02, 20262.832.832.502.5282.45K
Dec 31, 20252.692.822.662.82133.96K
Dec 30, 20252.712.722.552.70139.14K
Dec 29, 20252.622.752.502.68121.04K
Dec 26, 20252.752.892.652.6959.47K
Dec 24, 20252.542.852.492.73161.9K
Dec 23, 20252.512.612.402.60152.17K
Dec 22, 20252.252.652.252.54228.28K
Dec 19, 20252.282.402.112.27247.2K
Dec 17, 20252.362.382.032.25233.23K
Dec 16, 20252.262.362.262.3686.3K
Dec 15, 20252.512.512.272.3556.97K
Dec 12, 20252.422.562.402.50114.62K
Dec 11, 20252.362.492.272.43104.16K
Dec 10, 20252.382.382.312.3583.51K

Contact Details

Taicang, 215400

China

https://www.connectbiopharm.com865 125 3577866

About Company

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Company Information

Employees62
Beta-0.18
Sales or Revenue$0.00
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

REGN
-4.46-0.56%
Regeneron Pharmaceuticals, Inc.$796.55ARGX
-7.07997-0.89%
argenx SE$788.49MDGL
-42.16-7.58%
Madrigal Pharmaceuticals, Inc.$514.06UTHR
-7.6-1.55%
United Therapeutics Corporation$483.23VRTX
-5.82-1.24%
Vertex Pharmaceuticals Incorporated$463.86ALNY
-1.11-0.28%
Alnylam Pharmaceuticals, Inc.$398.29KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX
-5.93-2.01%
Praxis Precision Medicines, Inc.$288.45KRYS
12.5+5.02%
Krystal Biotech, Inc.$261.41SGEN
-0.16-0.07%
Seagen Inc.$228.74

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -12.39%, SMA50 -7.72%, SMA200 36.11%). The stock’s 14-day RSI is 39.94 (weak momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.45% below its high and over 321.57% above its low. Average 10-day trading volume of 59.58 thousand shares is below the 3-month average of 277.41 thousand, indicating normal recent market interest.

Earnings & Analyst Outlook

Connect Biopharma Holdings Limited generated EPS of -$0.28 over the past year. Five-year average earnings growth is 7.78%. The latest quarter delivered EPS of -$0.23. The next quarter is forecast at -$0.30. Next year's EPS is expected at $97.80. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $7.00. The high target offers 365.12% upside. The low target suggests 225.58% downside. The mean target is $8.67. This offers 303.26% upside. Connect Biopharma Holdings Limited earnings surprise history is frequent misses against expectations. The quarter that ended August 13, 2025, missed forecasts by 4.55%. The prior quarter beat by -29.63%. Over the last six quarters, Apple has recorded several small beats. These include -99.88% in March 28, 2024.

Shareholding & Insider Activity

Connect Biopharma Holdings Limited has 55.72 million shares outstanding. The public float is 14.34 million shares, elevated short interest at 0.29% of float. This equals 102.42 thousand shares. The short ratio is 0.44 days. Institutional investors hold 74.4% of the float. Insiders own 40.53%.

Financial & Profitability Overview

Over the trailing twelve months, Connect Biopharma has not generated any revenue. Returns are negative, with ROA at -65.77% and ROE at 25.10%.
On valuation metrics, Connect Biopharma trades at a P/E of -3.30, P/S of 61.32 and P/B of 1.67. The current ratio is 7.24 and quick ratio is 7.24. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -4526.36 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -32.38.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Connect Biopharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $805.59M (margin 0.0%). Net income was- $797.06M (EPS - $14.50).
The company ended the quarter with $1.13B in cash and short-term investments, a total debt of $3.00M, and net debt of - $547.28M. Total assets were $1.21B, with equity of - $3.18B. Financials further reflected weakness, with operating cash flow of - $47.93M, free cash flow of - $48.22M, and capital expenditures of - $294.00K.

Frequently Asked Questions

What is the current Connect Biopharma Holdings Limited (CNTB) stock price?
Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock price is $2.15 in the last trading session. During the trading session, CNTB stock reached the peak price of $2.25 while $2.15 was the lowest point it dropped to. The percentage change in CNTB stock occurred in the recent session was -3.59% while the dollar amount for the price change in CNTB stock was - $0.08.
CNTB's industry and sector of operation?
The NASDAQ listed CNTB is part of Biotechnology industry that operates in the broader Healthcare sector. Connect Biopharma Holdings Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CNTB?
Mr. Steven Chan
Chief Financial Officer
Dr. Chin Lee M.D., M.P.H.
Chief Medical Officer
Mr. Jiang Bian J.D.
Gen. Counsel & Chief Compliance Officer
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, Pres & Chairman of Directors
Dr. Raul Collazo Ph.D.
Vice President & Global Head of Medical Affairs
Dr. Lei Sun Ph.D.
Vice President of Biologics & Head of CMC
Dr. Malinda V. Longphre Ph.D.
Vice President & Head of US Clinical Operations
Dr. Zheng Wei Ph.D.
Co-Founder, Chief Executive Officer & Director
How CNTB did perform over past 52-week?
CNTB's closing price is 321.57% higher than its 52-week low of $0.51 where as its distance from 52-week high of $3.28 is -34.45%.
How many employees does CNTB have?
Number of CNTB employees currently stands at 62.
Link for CNTB official website?
Official Website of CNTB is: https://www.connectbiopharm.com
How do I contact CNTB?
CNTB could be contacted at phone 865 125 3577866 and can also be accessed through its website. CNTB operates from East R&D Building, Taicang, 215400, China.
How many shares of CNTB are traded daily?
CNTB stock volume for the day was 38.44K shares. The average number of CNTB shares traded daily for last 3 months was 274.78K.
What is the market cap of CNTB currently?
The market value of CNTB currently stands at $120.18M with its latest stock price at $2.15 and 55.9M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph